RN1005

RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration. It is being progressed towards the clinic partly funded by a 2009 competitive grant award from the Technology Strategy Board (TSB).